Skip to main content
main-content

24.09.2019 | Original Research | Ausgabe 6/2019 Open Access

Diabetes Therapy 6/2019

Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study

Zeitschrift:
Diabetes Therapy > Ausgabe 6/2019
Autoren:
Rikke Tetzschner, Ajenthen G. Ranjan, Signe Schmidt, Kirsten Nørgaard
Wichtige Hinweise

Enhanced Digital Features

To view enhanced digital features for this article go to https://​doi.​org/​10.​6084/​m9.​figshare.​9862100.
Rikke Tetzschner and Ajenthen G. Ranjan are co-first authors.

Abstract

Introduction

Intensive insulin treatment for type 1 diabetes is associated with high risk of mild hypoglycemia. Mild hypoglycemia is usually treated orally with glucose, which may contribute to weight gain. Subcutaneous injection of low-dose glucagon may be a new treatment option for some occasions of mild hypoglycemia in individuals aiming for optimal glycemic control without gaining weight. We investigated under which occasions patients were interested to use low-dose glucagon.

Methods

In a prospective 2-week event-driven survey, participants registered every event of mild hypoglycemia (sensor or blood glucose ≤ 3.9 mmol/l and/or hypoglycemia symptoms). For each hypoglycemia event, participants registered whether they would have preferred to use low-dose glucagon if the treatment had been available.

Results

A total of 51 participants (13 men, mean ± SD age 43.6 ± 12.5 years, HbA1c 7.3 ± 0.7% (57 ± 8 mmol/mol), BMI 24.9 ± 3 kg/m2) were included. Each participant had on average 10 (range 3–23) mild hypoglycemia events during the 2-week survey period. Glucagon was preferred in 58% of the 514 mild hypoglycemia events (p > 0.05). Twelve percent of the participants had no desire to use glucagon for any hypoglycemia event. The preference pattern did not differ between sex, patient treatment modalities, and possible causes for hypoglycemia (all p > 0.05).

Conclusion

This study showed that a majority of our participants with type 1 diabetes were interested in using low-dose glucagon for the treatment of mild hypoglycemia.

Funding

This work was funded by a research grant from the Copenhagen University Hospital Hvidovre and by the Danish Diabetes Academy supported by the Novo Nordisk Foundation.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2019

Diabetes Therapy 6/2019 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise